Literature DB >> 26369513

Dementia: Cerebrospinal fluid biomarkers in dementias.

Peter Paul De Deyn1.   

Abstract

A new study describes a biomarker profile based on cerebrospinal fluid (CSF) tau and amyloid-β₁₋₄₂ in a uniquely large population with a variety of dementia diagnoses. This study confirms the differential diagnostic value of CSF biomarkers and further highlights the important neuropathological overlap between dementia aetiologies.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26369513     DOI： 10.1038/nrneurol.2015.175

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  10 in total

1.  Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank.

Authors:  Warren W Barker; Cheryl A Luis; Alice Kashuba; Mercy Luis; Dylan G Harwood; David Loewenstein; Carol Waters; Pat Jimison; Eugene Shepherd; Steven Sevush; Neil Graff-Radford; Douglas Newland; Murray Todd; Bayard Miller; Michael Gold; Kenneth Heilman; Leilani Doty; Ira Goodman; Bruce Robinson; Gary Pearl; Dennis Dickson; Ranjan Duara
Journal:  Alzheimer Dis Assoc Disord       Date:  2002 Oct-Dec       Impact factor: 2.703

2.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Clifford R Jack; Marilyn S Albert; David S Knopman; Guy M McKhann; Reisa A Sperling; Maria C Carrillo; Bill Thies; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

Review 3.  Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group.

Authors: 
Journal:  Neurobiol Aging       Date:  1998 Mar-Apr       Impact factor: 4.673

4.  Overdiagnosing Vascular Dementia using Structural Brain Imaging for Dementia Work-Up.

Authors:  Ellis Niemantsverdriet; Bart F E Feyen; Nathalie Le Bastard; Jean-Jacques Martin; Johan Goeman; Peter Paul De Deyn; Sebastiaan Engelborghs
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 5.  Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Authors:  Kaj Blennow; Bruno Dubois; Anne M Fagan; Piotr Lewczuk; Mony J de Leon; Harald Hampel
Journal:  Alzheimers Dement       Date:  2014-05-03       Impact factor: 21.566

6.  Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.

Authors:  Tobias Skillbäck; Bahman Y Farahmand; Christoffer Rosén; Niklas Mattsson; Katarina Nägga; Lena Kilander; Dorota Religa; Anders Wimo; Bengt Winblad; Jonathan M Schott; Kaj Blennow; Maria Eriksdotter; Henrik Zetterberg
Journal:  Brain       Date:  2015-06-30       Impact factor: 13.501

7.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.

Authors:  Geert De Meyer; Fred Shapiro; Hugo Vanderstichele; Eugeen Vanmechelen; Sebastiaan Engelborghs; Peter Paul De Deyn; Els Coart; Oskar Hansson; Lennart Minthon; Henrik Zetterberg; Kaj Blennow; Leslie Shaw; John Q Trojanowski
Journal:  Arch Neurol       Date:  2010-08

8.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Authors:  Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  Revising the definition of Alzheimer's disease: a new lexicon.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Jeffrey L Cummings; Steven T Dekosky; Pascale Barberger-Gateau; André Delacourte; Giovanni Frisoni; Nick C Fox; Douglas Galasko; Serge Gauthier; Harald Hampel; Gregory A Jicha; Kenichi Meguro; John O'Brien; Florence Pasquier; Philippe Robert; Martin Rossor; Steven Salloway; Marie Sarazin; Leonardo C de Souza; Yaakov Stern; Pieter J Visser; Philip Scheltens
Journal:  Lancet Neurol       Date:  2010-10-09       Impact factor: 44.182

Review 10.  The genetics and neuropathology of frontotemporal lobar degeneration.

Authors:  Anne Sieben; Tim Van Langenhove; Sebastiaan Engelborghs; Jean-Jacques Martin; Paul Boon; Patrick Cras; Peter-Paul De Deyn; Patrick Santens; Christine Van Broeckhoven; Marc Cruts
Journal:  Acta Neuropathol       Date:  2012-08-14       Impact factor: 17.088
  10 in total
  3 in total

1.  Targeted genetic analysis of cerebral blood flow imaging phenotypes implicates the INPP5D gene.

Authors:  Xiaohui Yao; Shannon L Risacher; Kwangsik Nho; Andrew J Saykin; Ze Wang; Li Shen
Journal:  Neurobiol Aging       Date:  2019-06-18       Impact factor: 4.673

2.  Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome.

Authors:  Alain D Dekker; Juan Fortea; Rafael Blesa; Peter P De Deyn
Journal:  Alzheimers Dement (Amst)       Date:  2017-03-20

3.  Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis.

Authors:  Jana Janssens; Yannick Vermeiren; Erik Fransen; Tony Aerts; Debby Van Dam; Sebastiaan Engelborghs; Peter P De Deyn
Journal:  Alzheimers Dement (Amst)       Date:  2018-02-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.